Cargando…

Effect of Reduced Versus Usual Lipid Emulsion Dosing on Bilirubin Neurotoxicity and Neurodevelopmental Impairment in Extremely Preterm Infants: Study Protocol for a Randomized Controlled Trial

BACKGROUND: Bilirubin neurotoxicity (BN) occurs in premature infants at lower total serum bilirubin levels than term infants and causes neurodevelopmental impairment. Usual dose lipid infusions in preterm infants may increase free fatty acids sufficiently to cause bilirubin displacement from albumin...

Descripción completa

Detalles Bibliográficos
Autores principales: Holzapfel, Lindsay, Arnold, Cody, Tyson, Jon, Shapiro, Steven, Reynolds, Eric, Pedroza, Claudia, Stephens, Emily, Kleinfeld, Alan, Huber, Andrew, Rysavy, Matthew, Khan, Amir, del Mar Romero Lopez, Maria
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Journal Experts 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10029123/
https://www.ncbi.nlm.nih.gov/pubmed/36945475
http://dx.doi.org/10.21203/rs.3.rs-2566352/v1
_version_ 1784910079254855680
author Holzapfel, Lindsay
Arnold, Cody
Tyson, Jon
Shapiro, Steven
Reynolds, Eric
Pedroza, Claudia
Stephens, Emily
Kleinfeld, Alan
Huber, Andrew
Rysavy, Matthew
Khan, Amir
del Mar Romero Lopez, Maria
author_facet Holzapfel, Lindsay
Arnold, Cody
Tyson, Jon
Shapiro, Steven
Reynolds, Eric
Pedroza, Claudia
Stephens, Emily
Kleinfeld, Alan
Huber, Andrew
Rysavy, Matthew
Khan, Amir
del Mar Romero Lopez, Maria
author_sort Holzapfel, Lindsay
collection PubMed
description BACKGROUND: Bilirubin neurotoxicity (BN) occurs in premature infants at lower total serum bilirubin levels than term infants and causes neurodevelopmental impairment. Usual dose lipid infusions in preterm infants may increase free fatty acids sufficiently to cause bilirubin displacement from albumin, increasing passage of unbound bilirubin (UB) into the brain leading to BN and neurodevelopmental impairment not reliably identifiable in infancy. These risks may be influenced by whether cycled or continuous phototherapy is used to control bilirubin levels. OBJECTIVE: To assess differences in wave V latency measured by brainstem auditory evoked responses (BAER) at 34–36 weeks gestational age in infants born ≤750 g or <27 weeks’ gestational age randomized to receive usual or reduced dose lipid emulsion (half of the usual dose) irrespective of whether cycled or continuous phototherapy is administered. METHODS: Pilot factorial randomized controlled trial (RCT) of lipid dosing (usual and reduced) with treatment groups balanced between cycled or continuous phototherapy assignment. Eligible infants are born at ≤750 g or <27 weeks’ gestational age enrolled in the NICHD Neonatal Research Network RCT of cycled or continuous phototherapy. Infants will randomize 1:1 to reduced or usual dose lipid assignment during the first 2 weeks after birth and stratified by phototherapy assignment. Free fatty acids and UB will be measured daily using a novel probe. BAER testing will be performed at 34–36 weeks postmenstrual age or prior to discharge. Blinded neurodevelopmental assessments will be performed at 22–26 months. Intention-to-treat analyses will be performed with generalized linear mixed models with lipid dose and phototherapy assignments as random effects covariates, and assessment for interactions. Bayesian analyses will be performed as a secondary analysis. DISCUSSION: Pragmatic trials are needed to evaluate whether lipid emulsion dosing modifies the effect of phototherapy on BN. This factorial design presents a unique opportunity to evaluate both therapies and their interaction. This study aims to address basic controversial questions about the relationships between lipid administration, free fatty acids, UB, and BN. Findings suggesting a reduced lipid dose can diminish the risk of BN would support the need for a large multicenter RCT of reduced versus usual lipid dosing.
format Online
Article
Text
id pubmed-10029123
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher American Journal Experts
record_format MEDLINE/PubMed
spelling pubmed-100291232023-03-22 Effect of Reduced Versus Usual Lipid Emulsion Dosing on Bilirubin Neurotoxicity and Neurodevelopmental Impairment in Extremely Preterm Infants: Study Protocol for a Randomized Controlled Trial Holzapfel, Lindsay Arnold, Cody Tyson, Jon Shapiro, Steven Reynolds, Eric Pedroza, Claudia Stephens, Emily Kleinfeld, Alan Huber, Andrew Rysavy, Matthew Khan, Amir del Mar Romero Lopez, Maria Res Sq Article BACKGROUND: Bilirubin neurotoxicity (BN) occurs in premature infants at lower total serum bilirubin levels than term infants and causes neurodevelopmental impairment. Usual dose lipid infusions in preterm infants may increase free fatty acids sufficiently to cause bilirubin displacement from albumin, increasing passage of unbound bilirubin (UB) into the brain leading to BN and neurodevelopmental impairment not reliably identifiable in infancy. These risks may be influenced by whether cycled or continuous phototherapy is used to control bilirubin levels. OBJECTIVE: To assess differences in wave V latency measured by brainstem auditory evoked responses (BAER) at 34–36 weeks gestational age in infants born ≤750 g or <27 weeks’ gestational age randomized to receive usual or reduced dose lipid emulsion (half of the usual dose) irrespective of whether cycled or continuous phototherapy is administered. METHODS: Pilot factorial randomized controlled trial (RCT) of lipid dosing (usual and reduced) with treatment groups balanced between cycled or continuous phototherapy assignment. Eligible infants are born at ≤750 g or <27 weeks’ gestational age enrolled in the NICHD Neonatal Research Network RCT of cycled or continuous phototherapy. Infants will randomize 1:1 to reduced or usual dose lipid assignment during the first 2 weeks after birth and stratified by phototherapy assignment. Free fatty acids and UB will be measured daily using a novel probe. BAER testing will be performed at 34–36 weeks postmenstrual age or prior to discharge. Blinded neurodevelopmental assessments will be performed at 22–26 months. Intention-to-treat analyses will be performed with generalized linear mixed models with lipid dose and phototherapy assignments as random effects covariates, and assessment for interactions. Bayesian analyses will be performed as a secondary analysis. DISCUSSION: Pragmatic trials are needed to evaluate whether lipid emulsion dosing modifies the effect of phototherapy on BN. This factorial design presents a unique opportunity to evaluate both therapies and their interaction. This study aims to address basic controversial questions about the relationships between lipid administration, free fatty acids, UB, and BN. Findings suggesting a reduced lipid dose can diminish the risk of BN would support the need for a large multicenter RCT of reduced versus usual lipid dosing. American Journal Experts 2023-03-07 /pmc/articles/PMC10029123/ /pubmed/36945475 http://dx.doi.org/10.21203/rs.3.rs-2566352/v1 Text en https://creativecommons.org/licenses/by/4.0/This work is licensed under a Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by/4.0/) , which allows reusers to distribute, remix, adapt, and build upon the material in any medium or format, so long as attribution is given to the creator. The license allows for commercial use. https://creativecommons.org/licenses/by/4.0/License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License (https://creativecommons.org/licenses/by/4.0/)
spellingShingle Article
Holzapfel, Lindsay
Arnold, Cody
Tyson, Jon
Shapiro, Steven
Reynolds, Eric
Pedroza, Claudia
Stephens, Emily
Kleinfeld, Alan
Huber, Andrew
Rysavy, Matthew
Khan, Amir
del Mar Romero Lopez, Maria
Effect of Reduced Versus Usual Lipid Emulsion Dosing on Bilirubin Neurotoxicity and Neurodevelopmental Impairment in Extremely Preterm Infants: Study Protocol for a Randomized Controlled Trial
title Effect of Reduced Versus Usual Lipid Emulsion Dosing on Bilirubin Neurotoxicity and Neurodevelopmental Impairment in Extremely Preterm Infants: Study Protocol for a Randomized Controlled Trial
title_full Effect of Reduced Versus Usual Lipid Emulsion Dosing on Bilirubin Neurotoxicity and Neurodevelopmental Impairment in Extremely Preterm Infants: Study Protocol for a Randomized Controlled Trial
title_fullStr Effect of Reduced Versus Usual Lipid Emulsion Dosing on Bilirubin Neurotoxicity and Neurodevelopmental Impairment in Extremely Preterm Infants: Study Protocol for a Randomized Controlled Trial
title_full_unstemmed Effect of Reduced Versus Usual Lipid Emulsion Dosing on Bilirubin Neurotoxicity and Neurodevelopmental Impairment in Extremely Preterm Infants: Study Protocol for a Randomized Controlled Trial
title_short Effect of Reduced Versus Usual Lipid Emulsion Dosing on Bilirubin Neurotoxicity and Neurodevelopmental Impairment in Extremely Preterm Infants: Study Protocol for a Randomized Controlled Trial
title_sort effect of reduced versus usual lipid emulsion dosing on bilirubin neurotoxicity and neurodevelopmental impairment in extremely preterm infants: study protocol for a randomized controlled trial
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10029123/
https://www.ncbi.nlm.nih.gov/pubmed/36945475
http://dx.doi.org/10.21203/rs.3.rs-2566352/v1
work_keys_str_mv AT holzapfellindsay effectofreducedversususuallipidemulsiondosingonbilirubinneurotoxicityandneurodevelopmentalimpairmentinextremelypreterminfantsstudyprotocolforarandomizedcontrolledtrial
AT arnoldcody effectofreducedversususuallipidemulsiondosingonbilirubinneurotoxicityandneurodevelopmentalimpairmentinextremelypreterminfantsstudyprotocolforarandomizedcontrolledtrial
AT tysonjon effectofreducedversususuallipidemulsiondosingonbilirubinneurotoxicityandneurodevelopmentalimpairmentinextremelypreterminfantsstudyprotocolforarandomizedcontrolledtrial
AT shapirosteven effectofreducedversususuallipidemulsiondosingonbilirubinneurotoxicityandneurodevelopmentalimpairmentinextremelypreterminfantsstudyprotocolforarandomizedcontrolledtrial
AT reynoldseric effectofreducedversususuallipidemulsiondosingonbilirubinneurotoxicityandneurodevelopmentalimpairmentinextremelypreterminfantsstudyprotocolforarandomizedcontrolledtrial
AT pedrozaclaudia effectofreducedversususuallipidemulsiondosingonbilirubinneurotoxicityandneurodevelopmentalimpairmentinextremelypreterminfantsstudyprotocolforarandomizedcontrolledtrial
AT stephensemily effectofreducedversususuallipidemulsiondosingonbilirubinneurotoxicityandneurodevelopmentalimpairmentinextremelypreterminfantsstudyprotocolforarandomizedcontrolledtrial
AT kleinfeldalan effectofreducedversususuallipidemulsiondosingonbilirubinneurotoxicityandneurodevelopmentalimpairmentinextremelypreterminfantsstudyprotocolforarandomizedcontrolledtrial
AT huberandrew effectofreducedversususuallipidemulsiondosingonbilirubinneurotoxicityandneurodevelopmentalimpairmentinextremelypreterminfantsstudyprotocolforarandomizedcontrolledtrial
AT rysavymatthew effectofreducedversususuallipidemulsiondosingonbilirubinneurotoxicityandneurodevelopmentalimpairmentinextremelypreterminfantsstudyprotocolforarandomizedcontrolledtrial
AT khanamir effectofreducedversususuallipidemulsiondosingonbilirubinneurotoxicityandneurodevelopmentalimpairmentinextremelypreterminfantsstudyprotocolforarandomizedcontrolledtrial
AT delmarromerolopezmaria effectofreducedversususuallipidemulsiondosingonbilirubinneurotoxicityandneurodevelopmentalimpairmentinextremelypreterminfantsstudyprotocolforarandomizedcontrolledtrial